[go: up one dir, main page]

WO2010117194A3 - Composition for preventing or treating gastric disorders containing an active component comprising a fatty acid series compound - Google Patents

Composition for preventing or treating gastric disorders containing an active component comprising a fatty acid series compound Download PDF

Info

Publication number
WO2010117194A3
WO2010117194A3 PCT/KR2010/002105 KR2010002105W WO2010117194A3 WO 2010117194 A3 WO2010117194 A3 WO 2010117194A3 KR 2010002105 W KR2010002105 W KR 2010002105W WO 2010117194 A3 WO2010117194 A3 WO 2010117194A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
composition
fatty acid
active component
treating gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/002105
Other languages
French (fr)
Korean (ko)
Other versions
WO2010117194A2 (en
Inventor
최원식
장도연
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHUNG SEE-NAM
Original Assignee
CHUNG SEE-NAM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHUNG SEE-NAM filed Critical CHUNG SEE-NAM
Publication of WO2010117194A2 publication Critical patent/WO2010117194A2/en
Publication of WO2010117194A3 publication Critical patent/WO2010117194A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a composition for protecting the stomach wall and for preventing or treating gastric disorders, containing an active component comprising a fatty acid series compound which is effective in protecting the stomach wall and treating gastric disorders.
PCT/KR2010/002105 2009-04-06 2010-04-06 Composition for preventing or treating gastric disorders containing an active component comprising a fatty acid series compound Ceased WO2010117194A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0029405 2009-04-06
KR1020090029405A KR20100111040A (en) 2009-04-06 2009-04-06 Composition for prevention or treatment of gastrointestinal disease containing a fatty acid-based compound

Publications (2)

Publication Number Publication Date
WO2010117194A2 WO2010117194A2 (en) 2010-10-14
WO2010117194A3 true WO2010117194A3 (en) 2011-03-17

Family

ID=42936709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002105 Ceased WO2010117194A2 (en) 2009-04-06 2010-04-06 Composition for preventing or treating gastric disorders containing an active component comprising a fatty acid series compound

Country Status (2)

Country Link
KR (1) KR20100111040A (en)
WO (1) WO2010117194A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738496T3 (en) * 2013-02-21 2020-01-23 Univ Kyoto Protective agent of the intestinal tract comprising a hydroxylated fatty acid
EP2848251B1 (en) 2013-09-12 2017-04-19 King Saud University Extracts and isolated compounds from Cakile arabica for treatment of ulcer
CN105232506A (en) * 2015-11-04 2016-01-13 温州医科大学 Application of butyric acid and salts thereof in preparation of medicine for treating or preventing gastric ulcer
CN105769840B (en) * 2016-04-01 2018-06-29 温州医科大学 The application of acetic acid and its salt
KR20180051736A (en) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 Composition comprising omega-3 polyunsaturated fatty acid as active ingredient about Helicobacter pylori-associated gastritis-cancer
IT201700089258A1 (en) 2017-08-02 2019-02-02 Pharmanutra S P A Composition for use in the prevention and treatment of iron deficiency
IT201900007329A1 (en) * 2019-05-27 2020-11-27 Alesco Srl Compositions comprising cetylated fatty acids for use in the treatment of the gastric mucosa, diabetes and high blood glucose levels
IT201900007311A1 (en) 2019-05-27 2020-11-27 Alesco Srl Process for the preparation of a composition comprising cetylated fatty acids
IT201900007326A1 (en) 2019-05-27 2020-11-27 Alesco Srl Compositions comprising cetylated fatty acids and their use in the treatment of arthritis and joint inflammatory states
KR102625873B1 (en) * 2023-01-27 2024-01-16 한국생명공학연구원 Composition for preventing, treating or improving sarcopenia and method for diagnosing sarcopenia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101294A2 (en) * 1982-08-09 1984-02-22 The Regents Of The University Of California Composition for protecting and healing gastro-duodenal mucosa and the liver of mammals
WO1995026646A1 (en) * 1994-04-01 1995-10-12 Abbott Laboratories Nutritional product for treatment of ulcerative colitis and use thereof
US5660842A (en) * 1994-10-04 1997-08-26 Bristol-Myers Squibb Company Inhibition of helicobacter
JPH10130161A (en) * 1996-09-06 1998-05-19 Otsuka Pharmaceut Co Ltd Composition against helicobacter pylori
KR20050079791A (en) * 2004-02-06 2005-08-11 에이치엔엠바이오(주) Anti-helicobacter composition containing mushroom extract

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101294A2 (en) * 1982-08-09 1984-02-22 The Regents Of The University Of California Composition for protecting and healing gastro-duodenal mucosa and the liver of mammals
WO1995026646A1 (en) * 1994-04-01 1995-10-12 Abbott Laboratories Nutritional product for treatment of ulcerative colitis and use thereof
US5660842A (en) * 1994-10-04 1997-08-26 Bristol-Myers Squibb Company Inhibition of helicobacter
JPH10130161A (en) * 1996-09-06 1998-05-19 Otsuka Pharmaceut Co Ltd Composition against helicobacter pylori
KR20050079791A (en) * 2004-02-06 2005-08-11 에이치엔엠바이오(주) Anti-helicobacter composition containing mushroom extract

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDWARD N. SIGUEL ET AL.: "Prevalence of essential fatty acid deficiency in patients with chronic gastrointestinal disorder", METABOLISM, vol. 45, no. 1, January 1996 (1996-01-01), pages 12 - 23 *
VASILEIO A PAGKALOS ET AL.: "Fatty acid composition of subcutaneous adipose tissue and gastric mucosa: Is there a relation with gastric ulceration?", BMC GASTROENTEROLOGY, vol. 9, no. 9, 23 January 2009 (2009-01-23), pages 1 - 9 *

Also Published As

Publication number Publication date
WO2010117194A2 (en) 2010-10-14
KR20100111040A (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010117194A3 (en) Composition for preventing or treating gastric disorders containing an active component comprising a fatty acid series compound
EP3354640A3 (en) Mif inhibitors and their uses
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
IL213747A0 (en) Fatty acid amide hydrolase inhibitor compounds, compositions comprising the same and uses thereof
WO2012080017A3 (en) Water-containing antiperspirant compositions with improved white mark protection
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
IL217828B (en) Crystalline molecular complex of zoledronic acid, lysine, and water, pharmaceutical compositions comprising the same and uses thereof
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2011107186A3 (en) Compounds for electronic devices
WO2008112199A8 (en) Method for inhibiting topoisomerase ii
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2008070268A3 (en) Pharmaceutical compositions
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
WO2011037411A3 (en) Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders
WO2011126250A3 (en) Composition containing pde5 inhibitor for relieving skin wrinkles
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761855

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10761855

Country of ref document: EP

Kind code of ref document: A2